Seek Returns

BBIO vs. GILD: BridgeBio Pharma vs. Gilead Sciences Stock Comparison

How do BridgeBio Pharma (BBIO) and Gilead Sciences (GILD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BridgeBio Pharma (BBIO) and Gilead Sciences (GILD) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for BridgeBio Pharma (BBIO) and Gilead Sciences (GILD)
Profile ItemBBIOGILD
NameBridgeBio Pharma Inc.Gilead Sciences Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization14.47 billion USD207.00 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 27, 2019January 22, 1992
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BBIO
GILD
GSPC
Loading price history…
BridgeBio Pharma (BBIO) vs. Gilead Sciences (GILD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for BridgeBio Pharma (BBIO) and Gilead Sciences (GILD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for BridgeBio Pharma (BBIO) and Gilead Sciences (GILD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BridgeBio Pharma (BBIO) and Gilead Sciences (GILD)
MetricBBIOGILD
Total Return (1Y)22.70%45.69%
Total Return (3Y, Annualized)40.97%35.30%
Total Return (5Y, Annualized)8.25%25.00%

Risk Profile

Drawdown History

BBIO
GILD
GSPC
Loading price history…
BridgeBio Pharma (BBIO) vs. Gilead Sciences (GILD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for BridgeBio Pharma (BBIO) and Gilead Sciences (GILD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BridgeBio Pharma (BBIO) and Gilead Sciences (GILD)
MetricBBIOGILD
Volatility (1Y, Annualized)44.39%27.57%
Beta (5Y)0.930.36
Max Drawdown (5Y)-89.79%-26.59%
Avg. Volume (3M)2.68M5.98M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BBIO and GILD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BridgeBio Pharma (BBIO) and Gilead Sciences (GILD)
MetricBBIOGILD
Sharpe Ratio (1Y)0.411.50
Sortino Ratio (1Y)0.632.48

Profitability

ROE (TTM)

BridgeBio Pharma (BBIO) has no ROE value reported for this period; Gilead Sciences (GILD) reports a negative figure of -22.45%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
BBIO
--

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-22.45%

Max
109.18%
Q3
6.23%
GILD
-22.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
BridgeBio Pharma (BBIO) vs. Gilead Sciences (GILD): BBIO does not report ROE, so it has no value marker; GILD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Both BridgeBio Pharma (BBIO) at -59.84% and Gilead Sciences (GILD) at -12.46% report negative net margin values, usually indicating net losses over the period.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-59.84%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
BBIO
-59.84%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.46%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
GILD
-12.46%
Min
-17.05%
Loading chart…
BridgeBio Pharma (BBIO) vs. Gilead Sciences (GILD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Gilead Sciences (GILD) reports 42.43%, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-3.30%

Max
83.12%
Q3
14.77%
Median
0.00%
BBIO
-3.30%
Q1
-78.82%
Min
-207.40%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

42.43%

Max
83.12%
GILD
42.43%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
BridgeBio Pharma (BBIO) vs. Gilead Sciences (GILD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BridgeBio Pharma (BBIO) and Gilead Sciences (GILD)
MetricBBIOGILD
ROE (TTM)---22.45%
ROA (TTM)-13.97%13.47%
Net Margin (TTM)-59.84%-12.46%
Operating Margin (TTM)-3.30%42.43%
Gross Margin (TTM)94.34%79.95%

Growth

Revenue Growth

BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while Gilead Sciences (GILD) at 2.39% is closer to the peer norm — faster top-line expansion for BBIO.

Loading chart…
BridgeBio Pharma (BBIO) vs. Gilead Sciences (GILD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Gilead Sciences (GILD) reports EPS growth of 1,684.21%, ranked against its industry; BridgeBio Pharma (BBIO) has no EPS growth figure this period.

Loading chart…
BridgeBio Pharma (BBIO) vs. Gilead Sciences (GILD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for BridgeBio Pharma (BBIO) and Gilead Sciences (GILD)
MetricBBIOGILD
Revenue Growth (YoY)126.26%2.39%
Revenue Growth (3Y CAGR)86.30%2.57%
EPS Growth (YoY)--1,684.21%
EPS Growth (3Y CAGR)--23.04%

Financial Strength

Current Ratio (MRQ)

Both BridgeBio Pharma (BBIO) at 2.09 and Gilead Sciences (GILD) at 1.38 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.09

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BBIO
2.09
Min
0.10

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GILD
1.38
Min
0.10
Loading chart…
BridgeBio Pharma (BBIO) vs. Gilead Sciences (GILD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Gilead Sciences (GILD) carries debt-to-equity ratio of 2.02 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
BBIO
--

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.02

GILD
2.02
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
BridgeBio Pharma (BBIO) vs. Gilead Sciences (GILD): BBIO does not report debt-to-equity ratio, so it has no value marker; GILD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for BridgeBio Pharma (BBIO) and Gilead Sciences (GILD)
MetricBBIOGILD
Current Ratio (MRQ)2.091.38
Debt / Equity (MRQ)--2.02
Net Debt / EBITDA--1.25

Dividends

Dividend Yield (TTM)

BridgeBio Pharma (BBIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a yield of 1.94%, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

GILD
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BridgeBio Pharma (BBIO) vs. Gilead Sciences (GILD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

BridgeBio Pharma (BBIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a payout of 43.46%, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.46%

GILD
43.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BridgeBio Pharma (BBIO) vs. Gilead Sciences (GILD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BridgeBio Pharma (BBIO) and Gilead Sciences (GILD)
MetricBBIOGILD
Dividend Yield (TTM)0.00%1.94%
Dividend Payout Ratio (TTM)0.00%43.46%

Valuation

P/E Ratio (TTM)

Neither BridgeBio Pharma (BBIO) nor Gilead Sciences (GILD) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
BBIO
--

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
GILD
--
Loading chart…
BridgeBio Pharma (BBIO) vs. Gilead Sciences (GILD): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

On P/S ratio, both BridgeBio Pharma (BBIO) at 15.31 and Gilead Sciences (GILD) at 6.68 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.31

Max
58.18
Q3
25.77
BBIO
15.31
Median
7.30
Q1
3.01
Min
0.01

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
GILD
6.68
Q1
3.01
Min
0.01
Loading chart…
BridgeBio Pharma (BBIO) vs. Gilead Sciences (GILD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Gilead Sciences (GILD) reports 15.88, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-5.59

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BBIO
-5.59
Min
-5.59

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.88

GILD
15.88
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
BridgeBio Pharma (BBIO) vs. Gilead Sciences (GILD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BridgeBio Pharma (BBIO) and Gilead Sciences (GILD)
MetricBBIOGILD
P/E Ratio (TTM)----
P/S Ratio (TTM)15.316.68
P/B Ratio (MRQ)-5.5915.88
Free Cash Flow Yield (TTM)-1.98%5.16%